The FDA has designated the viral vector rAAVrh74, which Sarepta Therapeutics, Inc. (NASDAQ:SRPT) uses in its gene therapy ...

The company is one of the first to receive a “platform technology designation,” which could speed the review of certain gene ...

Fintel reports that on June 6, 2025, Scotiabank upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from Sector ...

The Platform Technology Designation, which predates the current FDA leadership, is designed to streamline the drug ...

Sarepta Therapeutics (SRPT) stock gains as Scotiabank upgrades it to Sector Outperform ting a compelling risk-reward setup. Read more here.

US rare disease meds developer Sarepta Therapeutics (Nasdaq: SRPT) revealed that its rAAVrh74 viral vector used in the ...

Sarepta Therapeutics’ gene therapy to treat limb girdle muscular dystrophy type 2E/R4 gets US FDA platform technology designation: Cambridge, Massachusetts Friday, June 6, 2025, ...

High-rolling investors have positioned themselves bullish on Sarepta Therapeutics (NASDAQ:SRPT), and it's important for retail traders to take note. \This activity came to our attention today ...

Analysts' ratings for Sarepta Therapeutics SRPT over the last quarter vary from bullish to bearish, as provided by 30 analysts. In the table below, you'll find a summary of their recent ratings ...

Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. The firm had revenue of $744.86 million during the quarter, compared to analyst estimates of $685.75 million.

The S&P 500 Index ($SPX) (SPY) today is up +1.23%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +1.34%, and the Nasdaq ...